Clinical Research Directory

Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Summary

Every year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy and modulators of signaling pathways. More than 50% of cancer patients will receive radiation therapy during the course of their illness, including radiotherapy aimed a palliating symptoms secondary to metastatic diseases. Therefore, there will be an increasing number of patients who will be receiving radiotherapy while they are still receiving molecular agents. A better understanding of the interaction of these two treatment modalities is needed.

Official title: Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies - Registry

Key Details

Conditions

Interventions

Locations (1)